VRBPAC recommends harmonizing COVID vaccines content
Acting upon the Food and Drug Administration’s (FDA) request, the FDA’s Vaccines and…
China approves eight biotech crops — a promising development
The Biotechnology Innovation Organization (BIO) has welcomed China’s positive development: The country has…
Bivalent boosters halve infection, hospitalization risk of XBB variants, studies show
Ahead of the U.S. Food and Drug Administration’s (FDA) meeting to discuss the…
Australian scientists work on helping the immune system kill cancer cells
Australian scientists are a step closer to finding new and more effective treatments…
Partnering is a big deal at the BIO CEO & Investor Conference in NYC, Feb. 6-7
Over the last 10 years, partnering has been an essential driver of the…
European lessons on drug price controls teach the U.S. how ‘not to do it’
In light of the drastic rebate hike prompted by inflation and COVID-driven increases…
EDITORS’ CHOICE
2022 was a challenging year for biotechnology. What’s in store for 2023?
The biotechnology industry is one of the riskiest and the most challenging—but it is also one of the few that…
Read moreLatest News
VRBPAC recommends harmonizing COVID vaccines content
Acting upon the Food and Drug Administration’s (FDA) request, the FDA’s Vaccines and Related Biological Products Advisory Committee (VRBPAC) decided…
China approves eight biotech crops — a promising development
The Biotechnology Innovation Organization (BIO) has welcomed China’s positive development: The country has decided to allow the import of biotech…
Bivalent boosters halve infection, hospitalization risk of XBB variants, studies show
Ahead of the U.S. Food and Drug Administration’s (FDA) meeting to discuss the nation’s COVID-19 vaccine strategy, two studies published…
Australian scientists work on helping the immune system kill cancer cells
Australian scientists are a step closer to finding new and more effective treatments for lymphoma and lung cancer after opening…
Partnering is a big deal at the BIO CEO & Investor Conference in NYC, Feb. 6-7
Over the last 10 years, partnering has been an essential driver of the U.S. biotech business, with external partnerships increasing…
HEALTH

COVID-19 forced us to reimagine pharma supply chains – and that’s a good thing.
BIO’s Chief Policy Officer John Murphy joined a panel hosted by The Hill to discuss how the pandemic affected drug supply chains and the opportunity to improve them going forward.
AGRICULTURE

CLIMATE CHANGE
Carbon removal technology is needed for reaching net zero
Reaching net zero is impossible without more plans and policies to remove carbon dioxide, says a report published yesterday by experts…
Read moreFEDERAL POLICY
STATE POLICY
2022 midterms recap: what happened and what the results mean for biotech
The 2022 midterms are officially behind us – so, what happened, and what does biotech need to know going into…
Read moreINTERNATIONAL
BIO’s VIEW
Partnering is a big deal at the BIO CEO & Investor Conference in NYC, Feb. 6-7
Over the last 10 years, partnering has been an essential driver of the U.S. biotech business, with external partnerships increasing…
Read more